In October 2019, the Ministry of Food and Drug Safety of Korea approved olaparib as a first-line maintenance treatment for patients newly diagnosed with advanced, platinum-sensitive epithelial ovarian cancer with BRCA1 or BRCA2 pathogenic or likely pathogenic variants. The gene discussed is BRCA2; the disease is ovarian carcinoma.